| 1 |
35506159 | Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis. | 2022 May 3 |
3 |
| 2 |
32778670 | Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. | 2020 Aug 10 |
1 |
| 3 |
29499902 | Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity. | 2018 Dec 14 |
1 |
| 4 |
30360603 | Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy | 2018 Oct 26 |
1 |
| 5 |
25869015 | Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. | 2016 Feb |
1 |
| 6 |
27269636 | Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. | 2016 Jun |
1 |
| 7 |
25554586 | Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis. | 2015 Mar |
1 |
| 8 |
26352872 | ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. | 2015 Dec |
1 |
| 9 |
23811769 | [Role of ABC efflux transporters in the oral bioavailability and drug-induced intestinal toxicity]. | 2013 |
1 |
| 10 |
23953030 | A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). | 2013 Nov |
4 |
| 11 |
21687948 | 'Genetic profiling' and ovarian cancer therapy (review). | 2011 Sep-Oct |
1 |
| 12 |
20602618 | Irinotecan pharmacogenomics. | 2010 Jul |
1 |
| 13 |
19349540 | Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. | 2009 Jun 1 |
1 |
| 14 |
18418374 | Pharmacogenetic pathway analysis of irinotecan. | 2008 Sep |
1 |
| 15 |
18690847 | Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. | 2008 Aug |
1 |
| 16 |
18981587 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). | 2008 Nov |
10 |
| 17 |
17185998 | Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. | 2007 Jan |
6 |
| 18 |
17534875 | Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. | 2007 Jul 1 |
2 |
| 19 |
16271446 | Pharmacogenetics of irinotecan metabolism and transport: an update. | 2006 Mar |
2 |
| 20 |
16343744 | Role of pharmacogenetics in irinotecan therapy. | 2006 Mar 8 |
1 |
| 21 |
16508919 | Expression of drug pathway proteins is independent of tumour type. | 2006 Jun |
1 |
| 22 |
15801936 | Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. | 2005 Apr |
1 |
| 23 |
16132345 | Human multidrug resistance associated protein 4 confers resistance to camptothecins. | 2005 Nov |
4 |
| 24 |
12914384 | Pharmacogenetics of stomach cancer. | 2003 Sep-Oct |
1 |
| 25 |
12199631 | Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. | 2002 Aug |
3 |
| 26 |
15618649 | The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. | 2002 |
4 |
| 27 |
10378768 | An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells. | 1999 Apr 26 |
2 |
| 28 |
10695015 | [Mechanisms for resistance to anticancer agents and the reversal of the resistance]. | 1999 Sep |
2 |